Walleye Capital
TBPH icon

Walleye Capital’s Theravance Biopharma TBPH Stock Holding History

Walleye Capital’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,000
Closed -$14.6K – 5116
2025
Q3 		$14.6K Buy
+1,000
New +$12.6K ﹤0.01% 4242
2022
Q4 		– Sell
-26,400
Closed -$268K – 3629
2022
Q3 		$268K Buy
+26,400
New +$247K 0.01% 1912

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Walleye Capital's TBPH Position: Q4 2025 in Review

Walleye Capital sold out of Theravance Biopharma (TBPH) in Q4 2025, closing a stake of 29,395 shares — an estimated $429K sold.

Walleye Capital first reported a position in TBPH in Q2 2021 and held it in 5 quarters. The position peaked at $750K in Q2 2022. 169 funds tracked by Wall St. Rank hold TBPH as of Q4 2025.

  • Walleye Capital reported no remaining Theravance Biopharma position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 29,395 Theravance Biopharma shares in Q4 2025, an estimated $429K.
  • Walleye Capital first reported a position in Theravance Biopharma in Q2 2021 and held it in 5 quarters.
  • Walleye Capital's Theravance Biopharma position peaked at $750K in Q2 2022.
  • 169 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.